Welcome to our dedicated page for KANE BIOTECH ORD news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on KANE BIOTECH ORD stock.
Kane Biotech Inc. (KNBIF) is a biotechnology company dedicated to researching, developing, and commercializing technologies and products that prevent and eliminate microbial biofilms. With a robust portfolio of intellectual property and products like StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™, the company is at the forefront of biofilm research. Recently, Kane Biotech announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel. The company is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.
Kane Biotech has entered into a licensing agreement with Skout’s Honor for its patented coactiv+™ technology, particularly in pet oral care applications. This ten-year agreement grants Skout’s Honor a non-exclusive license for use in North America, while STEM Animal Health, a joint venture of Kane Biotech, will continue to market its bluestem™ product line. As part of the agreement, STEM will receive a total of $500,000 USD in licensing fees plus ongoing royalties from Skout’s Honor's sales utilizing the coactiv+™ technology. This partnership is expected to enhance market reach and innovation in pet care products. However, Kevin Cole, president of STEM, will be leaving the company. Kane Biotech continues to focus on developing solutions targeting microbial biofilms.
Kane Biotech Inc. (OTCQB: KNBIF) will announce its Q4 and full-year 2022 financial results on April 20, 2023, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and business developments. Participants can register online for the call to receive dial-in details. Kane Biotech specializes in developing technologies to prevent and remove microbial biofilms, holding over 80 patents and trademarks. The company continues to focus on its research expertise to enhance its portfolio of biotechnologies and products.
Kane Biotech has signed a distribution agreement with Salud Pharma to launch its coactiv+™ Antimicrobial Hydrogel and DermaKB™ scalp care products in Colombia, Panama, and Costa Rica. The coactiv+™ product will be marketed through wound care centers and pharmacies after receiving FDA 510(k) approval. The DermaKB™ line addresses biofilm-related scalp conditions. This partnership aims to improve patient care in the region, responding to a significant need for advanced wound care solutions, given that over 80% of chronic wounds involve biofilm formation.
Kane Biotech reported third quarter 2022 financial results, achieving total revenue of $571,686, a 5% increase year-over-year. For the nine months ended September 30, 2022, revenue surged 65% to $1,976,698. License revenue soared 93% in Q3 to $69,411, while royalty revenue jumped 118% to $76,604. Gross profit rose 105% to $269,740 in Q3. Operating expenses decreased by 35% to $1,121,337. The company's loss narrowed 34% to $(1,039,091). Kane also submitted its first 510(k) application for the coactiv+™ Antimicrobial Wound Gel.
Kane Biotech Inc. (TSX-V: KNE; OTCQB: KNBIF) will release its Q3 2022 financial results on November 24, 2022. The management team will host a conference call at 4:30 p.m. ET to discuss the results and recent business developments. Investors can pre-register for the call to receive dial-in details. Kane Biotech specializes in technologies for preventing and eliminating microbial biofilms and holds 81 patents. The company continues to engage in research and development aimed at commercialization.
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) has submitted a 510(k) premarket notification to the FDA for its new coactiv+™ Antimicrobial Hydrogel, designed for sensitive chronic wounds. Using patented coactiv+™ technology, this hydrogel aims to alleviate the challenges of treating chronic wounds, which often involve bacterial biofilms that resist treatment. The company anticipates favorable FDA reception, highlighting the significance of this technology in addressing the healthcare burden of chronic wounds.
Kane Biotech Inc. (OTCQB: KNBIF) announced its presentation at the Symposium on Advanced Wound Care (SAWC) Fall forum in Las Vegas, happening from October 13-16, 2022. This event focuses on advancing wound care practices through collaboration among various medical professionals. Dr. Gregory Schultz highlighted the significance of their DispersinB® Hydrogel and coactiv+® Antimicrobial Hydrogel in enhancing wound healing by combating biofilm formation. Kane Biotech emphasizes its commitment to improving patient outcomes through innovative wound care technologies.
Kane Biotech has secured an additional $425,000 USD in funding for its DispersinB® Hydrogel, contributing to a total of $2.7 million USD in non-dilutive funding received since 2020. This financial backing from the U.S. Department of Defense aims to advance clinical trials for treating biofilm-mediated antimicrobial resistance in chronic wounds. The DispersinB® Hydrogel shows promise in inhibiting biofilm formation, potentially accelerating wound closure and improving military readiness. The company emphasizes the clinical significance of its product amidst the high costs of chronic wound treatment.
Kane Biotech reported its second quarter 2022 results, showcasing remarkable growth with total revenue reaching $839,579, up 201% year-over-year. License revenue surged 1,295% to $500,225, driven by a significant milestone from subsidiary STEM Animal Health achieving the VOHC Seal of Acceptance, resulting in $1.3 million in milestone payments. Gross profit increased 665% to $639,215, while total operating expenses rose 25% to $1,361,306. The company ended the quarter with $2.5 million in cash and secured $1 million from a private placement. Future developments include advancing clinical trials for its wound care technologies.
Kane Biotech Inc. (OTCQB: KNBIF) will announce its second quarter 2022 financial results on August 25, 2022, after market close. A conference call featuring management will take place at 4:30 p.m. ET to discuss the results and business developments. Investors can pre-register for the call via a provided link. Kane Biotech specializes in technologies that prevent and remove microbial biofilms and owns a robust portfolio of intellectual property, including 81 patents. For further information, visit their official website.
FAQ
What is the current stock price of KANE BIOTECH ORD (KNBIF)?
What is the market cap of KANE BIOTECH ORD (KNBIF)?
What is Kane Biotech Inc. known for?
What are some of the key products offered by Kane Biotech?
Where is Kane Biotech listed?
What recent achievements has Kane Biotech announced?
Who is the President and CEO of Kane Biotech?
What sets Kane Biotech apart in the biotechnology industry?
How can investors participate in Kane Biotech's growth?
What recent financial results has Kane Biotech shared?
Where can I find more information about Kane Biotech?
What industry does Kane Biotech operate in?
